Thomas Clozel is a visionary oncologist and entrepreneur, and a pioneer of agentic AI in life sciences. He is the co-founder and CEO of Owkin, where he leads the development of Owkin K, the world’s first biology-native AI scientist powered by a proprietary biology LLM and a multimodal data moat. Under his leadership, the company is accelerating drug discovery, enabling AI-driven therapies, and laying the foundations for Biological Artificial Superintelligence. Owkin is redefining how medical decisions and therapies are developed and delivered. Thomas is based in Geneva.